A Phase 3 interventional study of Icosapent ethyl (IPE) and Placebo in COVID19, sponsored by Estudios Clínicos Latino América. Completed at 1 site in Argentina. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Estudios Clínicos Latino América · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in COVID-19 with a site in Argentina — 6 open to participants now, 7 under way, 5 of them phase 3. COVID-19 · Argentina.
Among the 127 studies in COVID-19 with a site in Argentina, this one is the 6th largest by enrollment of the 87 interventional ones that give a count, is one of 70 that started in 2020, is one of 35 in phase 3, and was the 29th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 127 studies in COVID-19 with a site in Argentina are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in Argentina, United States, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
Pfizer · Sites in Argentina, United States, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in Argentina, United States, Belgium and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Argentina, United States, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in Argentina, United States, Australia and 36 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 42 · Phase 3 54 · Phase 4 4
First in 2020; this study’s year is marked. 70 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,093 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 414 across the 87 interventional studies, 503 across the 40 observational. Of the 102 that completed or were terminated, 41 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Estudios Clínicos Latino América is the lead sponsor of 3 studies on the registry; none are open to participants now.
Estudios Clínicos Latino América has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in Argentina that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 127 studies in COVID-19 with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PREPARE-IT investigator-initiated trial program is a simple, pragmatic, therapeutic strategy evaluating pure icosapent ethyl (IPE) at initially higher doses intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection due to COVID-19 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).
Few vaccines have received emergency authorization providing relative immunity, reducing both transmission and infection rates and subsequent associated morbidity and mortality. However, broad access to vaccines is limited globally, and emergence of COVID-19 viral mutations and vaccine breakthrough cases underscore the need for complementary effective therapies.
To date, there are limited systemic options available for effective treatment from viral-inhibitors, polyclonal antibodies (immunomodulatory drugs) to mitigate the inflammatory cascade and subsequent cytokine storm, and low-dose steroids such as dexamethasone in high-risk patients, which was associated with a reduction in mortality.
Icosapent ethyl (IPE) is a safe, well-tolerated oral therapy proven to be effective in improving outcomes in patients with established cardiovascular disease or diabetes with one or more additional risk factors.
In the context of COVID-19, a recent pilot study on 50 patients on a loading dose of 8g/day for three days, followed by 4g/daily showed a significant improvement in validated patient-reported FLU-PRO score symptoms. A corresponding reduction in a key biomarker of inflammation (hs-CRP) was also detected within the IPE arm at 14 days.
While this pilot study provides the first evidence of an early anti-inflammatory effect of IPE, to confirm these findings, we designed a randomized, placebo-controlled study program investigating IPE with a similar loading dose intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection from SARS-CoV-2 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).
(A) Prevention arm:
Inclusion Criteria:
Exclusion Criteria:
(B) Treatment arm:
Inclusion Criteria:
Exclusion Criteria:
Subjects who fill out the pre-selection form will be evaluated and approved for admission to the clinical trial after confirming their entry criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
Drug: Icosapent ethyl (IPE)
Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
Drug: Placebo
Participants in this arm will receive study medication IPE with the following dosage schedule: 8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Also known as: Vascepa®
Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
(A) Prevention Arm: SARS-CoV-2 positivity assesed up to day 60.
SARS-CoV-2 positive subjects are defined as subjects with positive tests for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies after developing COVID-19 disease at any stage within the follow-up period (including those subjects with or without symptomatic COVID-19 evaluated before the final visit) or those individuals who test positive for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies at the final visit (day 60).
Time frame: 60 days
(B) Treatment Arm: COVID 19 related hospitalization (indication for hospitalization per the blinded investigator or actual hospitalization) or death assessed up to 28 days
Time frame: 28 days
(A) Prevention Arm: High-sensitivity C-reactive Protein (mg/dL) change from baseline to day 60 (key secondary outcome)
Mean change from baseline will be computed
Time frame: baseline, 60 days
(A) Prevention Arm: Triglycerides (mg/dL) change from baseline to day 60
Mean change from baseline will be computed
Time frame: baseline, 60 days
(A) Prevention Arm: FLU-PRO SCORE change from baseline to day 60 in a subset of subjects
Mean change from baseline will be computed
Time frame: baseline, 60 days
(B) Treatment Arm: COVID 19 related hospitalization or death assessed up to 28 days (key secondary outcome)
Time frame: 28 days
(B) Treatment Arm: Alive and out of the hospital at 28 days.
Time frame: 28 days
(B) Treatment Arm: In hospital length of stay assessed up to 28 days
Time frame: 28 days
(B) Treatment Arm: New requirement of mechanical ventilation assed up to 28 days.
Time frame: 28 days
(B) Treatment Arm: Total events: non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), until day 28.
Time frame: 28 days
(B) Treatment Arm: Total mortality assessed up to 28 days
Time frame: 28 days
(B) Treatment Arm: FLU-PRO SCORE change from baseline at 28 days
Time frame: (B) Treatment Arm:
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Aug 2021, 12 months.
Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 12 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eicosapentaenoic acid ethyl ester
Estudios Clínicos Latino América